comparemela.com

Latest Breaking News On - Supernus pharmaceuticals stock performance - Page 1 : comparemela.com

Lazard Asset Management LLC Has $327,000 Stock Position in Supernus Pharmaceuticals, Inc (NASDAQ:SUPN)

Lazard Asset Management LLC increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 170.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,905 shares of the specialty pharmaceutical company’s stock after purchasing an additional 7,508 shares […]

Congress Asset Management Co MA Has $25 29 Million Stock Holdings in Supernus Pharmaceuticals, Inc (NASDAQ:SUPN)

Congress Asset Management Co. MA boosted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 19.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 917,164 shares of the specialty pharmaceutical company’s stock after buying an additional 147,105 shares during the […]

Legato Capital Management LLC Has $592,000 Holdings in Supernus Pharmaceuticals, Inc (NASDAQ:SUPN)

Legato Capital Management LLC decreased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 3.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,472 shares of the specialty pharmaceutical company’s stock after selling 837 shares during […]

Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Buy at StockNews com

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a hold rating to a buy rating in a report released on Wednesday. Separately, Piper Sandler raised their price target on shares of Supernus Pharmaceuticals from $42.00 to $43.00 and gave the company an overweight rating in a research report on Thursday, November 9th. […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.